Press Release
17 November 2026 08:00:00 CET

Vicore Pharma to Participate in the DNB Carnegie Nordic Healthcare Conference

Stockholm, Sweden & Cambridge, Mass., November 17, 2026 – Vicore Pharma Holding AB (Nasdaq Stockholm: VICO, Nasdaq US: VCRE), a clinical-stage biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced that the company will participate in the DNB Carnegie Nordic Healthcare Conference.

Location: Oslo, Norway

Format: Panel discussion and 1×1 meetings

Panel: Idiopathic Pulmonary Fibrosis | Three shots at reversing IPF **–** the Nordic fibrosis race

Date and time: Tuesday, November 24, 2026, 1:45–2:05 PM CET

Participant: Mikael Nygård, Chief Operating Officer

For further information, please contact:
Hans Jeppsson, Chief Financial Officer, +46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma Holding AB
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

Attachments
Vicore Pharma to Participate in the DNB Carnegie Nordic Healthcare Conference